An interventional study of intravenous reinstallation of cerebrospinal fluid in Subarachnoid Hemorrhage, Subarachnoid Hemorrhage, Aneurysmal and Vasospasm, Cerebral, sponsored by Medical University Innsbruck. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-27.
Sponsored by Medical University Innsbruck · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Subarachnoid Hemorrhage with a site in Austria — 3 open to participants now, 3 under way, none of them phase 3. Subarachnoid Hemorrhage · Austria.
Among the 14 studies in Subarachnoid Hemorrhage with a site in Austria, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 5 that started in 2020, is one of 5 with no phase, and was the 10th registered.
513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.
Browse Subarachnoid Hemorrhage studies →3 of the 14 studies in Subarachnoid Hemorrhage with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–80
Medical University of Vienna · Sites in Austria
Ages 18–95
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 59 across 266 interventional studies indexed under Subarachnoid Hemorrhage.
Median enrollment 247 across the 10 interventional studies, 80 across the 4 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 14 have an industry lead sponsor. The 10 most frequent:
Medical University Innsbruck is the lead sponsor of 187 studies on the registry; 48 are open to participants now.
Medical University Innsbruck has 1 study filed under Subarachnoid Hemorrhage — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Subarachnoid Hemorrhage with a site in Austria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The pathophysiological mechanisms of aneurysmal subarachnoid haemorrhage (aSAH) involve early brain injury (EBI) and delayed cerebral ischemia (DCI).
Several mechanisms contribute to EBI pathogenesis, including cell death, inflammatory response, oxidative stress, excitotoxicity, microcirculatory dysfunction, microthrombosis and cortical spreading depolarization. All are suggested to be linked due to common pathogenic pathways and direct interaction.
Despite advances in research of diagnostics and treatment strategies, brain injury remains the major cause of death and disability in SAH patients. There is no sufficient treatment of SAH and its devastating consequences known so far. Developing and improving diagnostic methods to monitor SAH patients and to evaluate efficacy of treatment strategies are essential in SAH research. These include neuroimaging, biomarkers, and other parameters such as invasive multimodal neuromonitoring and intraoperative electrophysiological monitoring.
Cerebral vasospasm (CV) - mostly responsible for DCI - can be depicted on angiograms. Altogether, tremendous efforts have been taken to conquer the occurrence and sustainability of CV. The mortality of patients suffering aSAH rises up to 50% if the patients' condition is critical (Hunt\&Hess (HH) Grade 5, WFNS Grade 5, modified Fisher Grade 4).
Reports of beneficial outcome in patients with pre-existing CSF shunting have been published. The hypothesis of early CSF reapplication to the bloodstream, in order to prevent CV seems to be positively approved by the mentioned reports. Nevertheless, no data could be found on the mechanisms of action in this phenomenon.
To confirm the presence of interaction of the mechanisms of EBI and evaluate the application of cerebrospinal fluid (CSF), a pilot clinical trial was planned. Due to the lack of validated animal models for aSAH it is necessary to perform the trial first-in-human. A pilot (proof of concept) trial - is done through inclusion of 10 patients with severe aSAH (≥HH4). According to clinical guidelines, these patients receive external ventricular drainages in order to drain CSF and lower intracranial pressure. An interim analysis of data will be performed after inclusion and treatment of 5 patients. Blood-/CSF-sampling for further analysis will be collected before, during and after treatment according to the study protocol.
Aneurysmal subarachnoid haemorrhage (aSAH) is associated with high morbidity and mortality with an incidence of 5-9 per 100,000 population. The incidence of aSAH peaks amongst those of 40-60 years1; aSAH carries a high overall mortality rate of up to 67%2 with only around half of the survivors able to live independently. Given the age-related incidence 3 and high morbidity and mortality, SAH has a high burden on society . Conventionally following SAH, treatment is directed to securing the aneurysm to prevent further re-bleed. In addition to the primary brain injury due to the rupture of the aneurysm the occurrence of cerebral vasospasm (VS) with narrowing of the brain supplying arteries potentially lading to brain ischemia is as well - known and serious complication following aSAH. The development of VS is thought to be caused by various factors. Interestingly, this is not an instant phenomenon occurring right after the hemorrhagic event. VS develops rather in a time dependent fashion with a peak incidence around 7-10 days following from acute event.
From angiographic studies, it is known that up to 70% of all patients with a aSAH will develop VS and in about 40% of these it will result in clinical deterioration and in 10-15% in permanent delayed ischemic neurologic deficits (DIND) leading to an increased morbidity 4, 5 and mortality
. Based on the fact that VS develops with a time delay, this is thought to provide a "therapeutic window" allowing to initiate measures for its prevention. However, in spite of intensive experimental and clinical research the investigators still do not have any effective treatment for the prevention of VS in patients with aSAH. Many concepts have been elaborated in the past, mostly based o sound pharmacologic considerations such as calcium antagonists (Nimodipin), antioxidants (Tirilazad) and endothelin antagonists (Clazosentan). In clinical trials, however, none of these drugs have shown a therapeutic effect on VS and most of them have been abandoned since then. The only exception is the use of oral Nimodipin, which is still used showing a marginal effect 6-8.
In contrast to all previous studies, which were based on the use of specific drugs, the present hypothesis is different. It is based on the assumption that the brain is a "privileged" organ, where the in- and outflow is regulated by discrete barrier mechanisms (e.g. blood-brain- barrier). In the event of aSAH - factors that are thought to play an important role in the development of VS are released into the CSF. However, it is not clear whether these factors will enter the systemic circulation. This is further supported by the clinical observation that in many patients with aSAH, acute disturbances of CSF circulation can be seen, often resulting in hydrocephalus. This in return can be treated by CSF flow diversion with the use of external ventricular drainage, which is a routine procedure in the management of aSAH patients.
Based on the assumption that those factors responsible for the development of VS are contained in the CSF, but do not enter the systemic circulation, it then might make sense to use the externally drained CSF for intravenous re-administration and thereby activating a systemic response mechanism with in turn could prevent the development of VS.
The potential therapeutic benefits outweigh any potential risks for patients with aSAH.
The proposed clinical study involves autologous CSF without any changes made to the liquid. The CSF will be taken from the external ventricular drain (EVD) under sterile environment and reinfused intravenously.
An interval of approximately 21 days will permit a timely review and evaluation of interim safety (after 5 patients) and tolerability data collected The potential benefit to patients is significant with reduced delayed cerebral infarction (DCI), improved cognition and cerebral function. As such, studies in patients with aSAH are warranted, with a view to establishing the optimal dose, safety and exploratory efficacy profiles.
This is a pilot trial involving higher grade (see inclusion criteria) aSAH patients.
The human brain is protected and enjoying privileged immune status. The blood-brain- barrier (BBB) leads to consequent isolation of brain tissue from humoral immunity. The brain is experiencing several major changes during rupture of a cerebral aneurysm. First, the intracranial pressure increases immediately, caused by the actual bleeding. Second, the extravasation of blood disrupts the BBB and several immunogenic molecules travel through the spontaneous rupture into the CSF. Additionally, microscopic particles of the vessel wall are present in the CSF as a consequence of the wall rupture. Usually, these potentially spasmogenic fractions are never encountered by the brain and the external surface of its vessels. Interestingly, the perioperative collection of blood in subarachnoid spaces does not induce vasospasm.
The investigators hypothesized that the reported steps were crucial for the formation of cerebral vasospasm.
This study will be conducted in compliance with the protocol and according to Good Clinical Practice and applicable regulatory standards. No deviation from the protocol will be implemented without the prior review and approval by the relevant ethics and regulatory authorities, except where it may be necessary to eliminate an immediate hazard to a research subject. In such case, the deviation will be reported to the relevant ethics and regulatory authorities as soon as possible.
Ten patients with an angiographically confirmed aSAH, who in addition are in need of early external ventricular drainage (routine procedure), irrespective of the clinical grade on admission and in whom definite treatment (clip ligation or interventional treatment) is achievable within 72 hours following aSAH.
Following aneurysm clip ligation, the predetermined amount of CSF (10ml) will be obtained under sterile conditions directly from the external ventricular drain and administered in a peripheral vein. To reduce the possibility of contamination, the application of CSF will be done immediately. In case of extensive intraventricular hemorrhage, causing the aspiration of clotted blood while obtaining CSF, the patient needs to be excluded from the trial.
A number of patients will have an EVD placed for clinical reasons. These patients would regularly have CSF sampling ranging from daily to twice weekly.
In this study, approximately 2 ml CSF will be taken and stored for translational study purposes (starting on day of EVD fitting) until day 21 or until the EVD is removed as per standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age: >18, \<90
Exclusion Criteria:
Non-aneurysmal SAH
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive reinstallation of CSF intravenously.
Other: intravenous reinstallation of cerebrospinal fluid
Subjects will not receive study intervention; CSF will be sampled and analyzed in comparison to the Interventional arm,
10ml of CSF will be taken under sterile conditions from the external ventricular drain and immediately administered intravenously.
Incidence of severe radiographic vasospasm
measured upon digital subtraction angiography
Time frame: 8 (+/- 1) day post SAH
Infectious complications
presence of infections complications according to the study intervention (intravenous administration)
Time frame: 7 days
Incidence of vasospasm-related morbidity / mortality
Defined by on of the following: DIND (confirmed by mGCS); cerebral infarction upon CT scan (day 14), need for anti-vasospasm therapy within 14 day post securing
Time frame: within 21 days post-aneurysm securing
Plan to share: No
Started Jan 2020 (actual). Primary completion is estimated for Feb 2025, 61 months after the start.
Of 59 non-industry interventional studies with no phase under Subarachnoid Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 69. This study's planned 61 months is above that.
Counting every sponsor, half of 69 studies reached it within 32 months; a quarter within 20 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University Innsbruck →